Welcome to our dedicated page for Addex Therapeutics SEC filings (Ticker: ADXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company focused on small-molecule allosteric modulators. As a foreign issuer listed on the NASDAQ Capital Market, Addex Therapeutics reports to the SEC using forms such as Form 20-F for annual reports and Form 6-K for current information.
Recent Form 6-K filings for Addex Therapeutics include press releases, unaudited interim condensed consolidated financial statements, and management’s discussion and analysis of financial condition and results of operations. These documents are often incorporated by reference into the company’s registration statements on Form F-3 and Form S-8, as disclosed in the filings. The company’s reports also emphasize that its business faces significant risks and refer readers to risk factors discussed in its Form 20-F.
On Stock Titan, Addex Therapeutics filings are updated from the SEC’s EDGAR system, and AI-generated summaries can help explain the structure and key points of lengthy documents. Users can review annual disclosures on Form 20-F, interim information and press releases furnished on Form 6-K, and other registered offerings referenced in the company’s F-3 and S-8 statements.
For those analyzing ADXN, this filings page offers a structured view of Addex Therapeutics’ regulatory history, including financial statement presentations, discussions of results of operations, and risk disclosures that the company highlights as important to understanding its business and prospects.
Addex Therapeutics Ltd (ADXN) filed a routine Form 6-K on 20 June 2025. The filing primarily serves two administrative purposes: (1) it makes available unaudited interim condensed consolidated financial statements, management’s discussion and analysis (MD&A), and a 19 June 2025 press release as Exhibits 99.1-99.3; and (2) it formally incorporates those exhibits by reference into the company’s existing shelf registration statement on Form F-3 (No. 333-255089) and employee share-plan registration statements on Form S-8 (Nos. 333-255124 and 333-272515).
The company re-iterates that investors should review the risk factors detailed in its Form 20-F for the year ended 31 December 2024, filed 15 May 2025, and cautions that forward-looking statements remain subject to those risks. No new financial metrics, guidance, or transactional announcements are included in this 6-K.
CEO Tim Dyer signed the report on behalf of the registrant.